Quinolines as Chemotherapeutic Agents for Leishmaniasis

Author(s): Kristie A. Reynolds, Wendy A. Loughlin, David J. Young

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 5 , 2013

Become EABM
Become Reviewer
Call for Editor


The development of leishmanicidal quinolines and their in vitro (promastigote and amastigote) and, where applicable, in vivo activities are reviewed. This survey provides a direct comparison of bioactivity across different species (e.g. L. donovani, L. amazonensis, L. chagasi, L infantum), and in different animal models (e.g. L. donovani Balb/c mice and L. donovani infected hamsters). The progress of selected quinolines through pre-clinical development and phase I/II trials, and the lead quinoline drugs sitamaquinine and Imiquimod, are discussed in conjunction with delivery systems and combination therapies.

Keywords: Leishmaniasis, quinolines, affordable chemotherapies

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 12 March, 2013
Page: [730 - 743]
Pages: 14
DOI: 10.2174/1389557511313050010
Price: $65

Article Metrics

PDF: 26